Glioblastoma study: Apixaban
Official title Venous Thromboembolism Prevention in Outpatients With Glioma
ClinicalTrials.gov ID: NCT05683808
What this study is testing
What is Apixaban?
An investigational blood‑thinning medication being studied to prevent blood clots in patients with newly diagnosed grade 4 glioma. It is designed to inhibit clotting factor Xa, reducing the formation of blood clots.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to see if apixaban can reduce the risk of blood clots in patients with newly diagnosed grade 4 glioma.
- Who it's for
- Adults newly diagnosed with grade 4 glioma (glioblastoma or astrocytoma).
- What's involved
- Participants will take apixaban and attend scheduled visits for monitoring and tests.
- Time commitment
- The study lasts several months, with regular clinic visits and blood tests as scheduled.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histologic diagnosis of malignant glioma, World Health Organization (WHO) grade 4, including glioblastoma and astrocytoma, based on recent biopsy or...
- Age 18 and old
- Karnofsky performance status (KPS) 60-100
- Acceptable labs, including platelets of greater than or equal to 100,000, glomerular filtration rate (GFR) greater than or equal to 25.
- Ability to provide informed consent.
You likely can't join if
- Evidence of deep venous thrombosis (DVT), pulmonary embolism (PE), or cerebral vein thrombosis (CVT) within 6 months prior to enrollment on the study.
- Pregnancy.
- Significant bleeding risk including: history of symptomatic intracranial hemorrhage, active bleeding at time of study registration, clinically...
- Allergy to apixaban or contraindication to prophylactic anticoagulation.
- Indication for full anticoagulation (i.e. atrial fibrillation, mechanical valve, etc.).
- Estimated life expectancy of \<3 months.
See the full eligibility criteria
- Histologic diagnosis of malignant glioma, World Health Organization (WHO) grade 4, including glioblastoma and astrocytoma, based on recent biopsy or resection.
- Age 18 and old
- Karnofsky performance status (KPS) 60-100
- Acceptable labs, including platelets of greater than or equal to 100,000, glomerular filtration rate (GFR) greater than or equal to 25.
- Ability to provide informed consent.
- Planning for treatment with radiation and chemotherapy.
- Evidence of deep venous thrombosis (DVT), pulmonary embolism (PE), or cerebral vein thrombosis (CVT) within 6 months prior to enrollment on the study.
- Pregnancy.
- Significant bleeding risk including: history of symptomatic intracranial hemorrhage, active bleeding at time of study registration, clinically significant bleeding within 14 days of study registration, intracranial...
- Allergy to apixaban or contraindication to prophylactic anticoagulation. Contraindications include patients who are currently on unfractionated heparin, low molecular weight heparin, heparin derivatives (examples...
- Indication for full anticoagulation (i.e. atrial fibrillation, mechanical valve, etc.).
- Estimated life expectancy of \<3 months.
The study team makes the final eligibility decision.
Where it is enrolling
- Burlington, Vermont, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Burlington, Vermont, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.